ASDEMİR, A. And ÖZGÜR, A. 2024. Combination of navitoclax (Bcl-2 and Bcl-xL inhibitor) and Debio-0932 (Hsp90 inhibitor) suppresses the viability of prostate cancer cells via induction of apoptotic signaling pathway. Medical Oncology , vol.41, no.4 .

ASDEMİR, A., & ÖZGÜR, A., (2024). Combination of navitoclax (Bcl-2 and Bcl-xL inhibitor) and Debio-0932 (Hsp90 inhibitor) suppresses the viability of prostate cancer cells via induction of apoptotic signaling pathway. Medical Oncology , vol.41, no.4.

ASDEMİR, AYDEMİR, And Aykut ÖZGÜR. "Combination of navitoclax (Bcl-2 and Bcl-xL inhibitor) and Debio-0932 (Hsp90 inhibitor) suppresses the viability of prostate cancer cells via induction of apoptotic signaling pathway," Medical Oncology , vol.41, no.4, 2024

ASDEMİR, AYDEMİR And ÖZGÜR, Aykut. "Combination of navitoclax (Bcl-2 and Bcl-xL inhibitor) and Debio-0932 (Hsp90 inhibitor) suppresses the viability of prostate cancer cells via induction of apoptotic signaling pathway." Medical Oncology , vol.41, no.4, 2024

ASDEMİR, A. And ÖZGÜR, A. (2024) . "Combination of navitoclax (Bcl-2 and Bcl-xL inhibitor) and Debio-0932 (Hsp90 inhibitor) suppresses the viability of prostate cancer cells via induction of apoptotic signaling pathway." Medical Oncology , vol.41, no.4.

@article{article, author={AYDEMİR ASDEMİR And author={Aykut ÖZGÜR}, title={Combination of navitoclax (Bcl-2 and Bcl-xL inhibitor) and Debio-0932 (Hsp90 inhibitor) suppresses the viability of prostate cancer cells via induction of apoptotic signaling pathway}, journal={Medical Oncology}, year=2024}